Research Article | Published:

Inhibition of human telomerase activity by peptide nucleic acids

Nature Biotechnology 14, 615–619 (1996) | Download Citation

Subjects

Abstract

We report the inhibition of human telomerase activity by peptide nucleic acids (PNAs). PNAs recognize the RNA component of human telomerase (hTR) and inhibit activity of the enzyme with IC50 values in the picomolar to nanomolar range. Inhibition depends on targeting exact functional boundaries of the hTR template and is 10- to 50-fold more efficient than inhibition by analogous phosphorothioate (PS) oligomers. In contrast to high selectivity of inhibition by PNAs, PS oligomers inhibit telomerase in a non-sequence-selective fashion. These results demonstrate that PNAs can control the enzymatic activity of ribonucleoproteins and possess important advantages relative to PS oligomers in both the affinity and the specificity of their recognition. These observations should facilitate the development of effective inhibitors of telomerase activity and affinity probes of telomerase structure.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

Rent or Buy

All prices are NET prices.

References

  1. 1.

    1991. Telomeres. Trends Biol. Sci. 16: 378–381.

  2. 2.

    1994. Mammalian telomere dynamics: healing, fragmentation shortening, and stabilization. Curr. Op. Genet, and Dev. 4: 203–211.

  3. 3.

    et al. 1995. Telomere shortening is associated with cell division in vitro and in vivo. Exp. Cell Res. 220: 194–200.

  4. 4.

    , , , and 1992. Telomere end-replication problem and cell aging. J. Mol. Biol. 225: 951–960.

  5. 5.

    et al. 1990. Structure and variability of human chromosome ends. Cell Biol. 10: 518–526.

  6. 6.

    , and 1990. Telomeres shorten during aging of human fibroblasts. Nature 345: 458–460.

  7. 7.

    , and 1995. Telomerase and DMA end replication: no longer a lagging strand problem? Science 269: 1533–1524.

  8. 8.

    1992. Telomerases. Ann. Rev. Biochem. 61: 113–129.

  9. 9.

    , and 1994. Stringent requirements for the formation of human telomeres. Proc. Natl. Acad. Sci. USA 91: 8861–8865.

  10. 10.

    et al. 1994. Specific association of human telomerase activity with immortal cells and cancer. Science 266: 2011–2015.

  11. 11.

    and 1995. Telomeres and telomerase in human cancer. Int. J. Oncol. 7: 423–432.

  12. 12.

    1995. Aging and cancer: are telomerases and telomerase the connection. Mol. Med. Today 1: 378–384.

  13. 13.

    and 1996. Telomerase activity in human cancer. Curr. Opin. Oncol. 8: 66–71.

  14. 14.

    et al. 1994. Cell immortality, telomerase and cancer. Cold Spring Harbor Symposia on Quantitative Biology 59: 307–315.

  15. 15.

    , , , , , and 1995. Correlation telomerase activity levels with human neuroblastoma outcomes. Nature Med. 1: 249–255.

  16. 16.

    , and 1995. Telomerase activity in normal and malignant hematopoietic cells. Proc. Natl. Acad. Sci. USA 92: 9082–9086.

  17. 17.

    , , , and 1995. Telomere elongation in immortal human cells without detectable telomerase activity. EMBO J. 14: 4240.

  18. 18.

    et al. 1995. The RNA component of human telomerase. Science 269: 1236–1239.

  19. 19.

    , and 1995. Purification of tetrahymena telomerase and cloning of genes encoding the two protein components of the enzyme. Cell 81: 677–686.

  20. 20.

    and 1990. Functional evidence for an RNA template in telomerase. Science 247: 546.

  21. 21.

    et al. 1992. Antisense and antigene properties of peptide nucleic acids. Science 258: 1481–1485.

  22. 22.

    , , , and 1991. Sequence-selective recognition of DMA by strand displacement with a thymine-substituted polyamide. Science 254: 1497–1500.

  23. 23.

    et al. 1993. PNA hybridizes to complementary oligonucleotides obeying the Watson-Crick hydrogen bonding rules. Nature 365: 566–568.

  24. 24.

    et al. 1994. Stability of peptide nucleic acids in human serum and cellular extracts. Biochem. Pharmacol. 48: 1310–1313.

  25. 25.

    et al 1995. Detection of telomerase activity in human cells and tumors by a telomeric repeat amplification protocol. Methods in Cell Science 17: 1–15.

  26. 26.

    , and 1995. Modifications of a telomeric repeat amplification protocol (TRAP) result in increased reliability, linearity, and sensitivity. Nucl. Acids Res. 23: 3794–3795.

  27. 27.

    1991. Recognition of a chromosome truncation site associated with α-thalassaemia by human telomerase. Nature 353: 454–456.

  28. 28.

    and Unpublished results.

  29. 29.

    and 1991. Binding of hairpin and dumbbell DMA to transcription factors. Nucl. Acids Res. 24: 6958.

  30. 30.

    , , and 1994. Ex vivo regulation of spe-cific gene expression by nanamolar concentration of double-stranded dumbbell oligonucleotides. J. Biol. Chem. 269: 16933–16937.

  31. 31.

    1995. Oligonucleotides as research, diagnostic, and therapeutic agents. J. Biol. Chem. 270: 13581–13584.

  32. 32.

    , , , , and , 1992. Selection of single-stranded DMA molecules that bind and inhibit human thrombin. Nature 355: 564–566.

  33. 33.

    , , , , , and 1995. Phospholipid membrane permeability of peptide nucleic acid. FEBS Lett. 356: 27–29.

  34. 34.

    et al. 1994. Synthesis of peptide nucleic acid monomers containing the four natural nucleobases. J. Org. Chem. 59: 5767–5773.

  35. 35.

    et al. 1995. Fmoc mediated synthesis of peptide nucleic acids. Tetrahedron 51: 6179–6194.

  36. 36.

    and 1992. Novel DNA superstructures formed by telomere-like oligomers. Biochemistry 31: 65–70.

  37. 37.

    and 1993. Characterization of a G-quartet formation reaction promoted by the β-subunit of the Oxytricha telomere-binding protein. Biochemistry 32: 11646–11657.

  38. 38.

    and 1993. Solution structure of the human telomeric repeat d[AG3(AG3)3] G-tetraplex. Structure 1: 263–281.

  39. 39.

    , , , and 1989. Stepwise mechanism of HIV reverse transcriptase: primer function of phosphorothioate oligodeoxyribonucleotides. Biochemistry 28: 1340–1346.

  40. 40.

    et al. 1994. Effect of phosphorothioate modification of oligo-deoxynucleotides on specific protein binding. J. Biol. Chem. 269: 26801–26805.

  41. 41.

    et al. 1995. Binding of phosphorothioate oligodeoxynucleotides to basic fibroblast growth factor, recombinant soluble CD4, laminin and fibronectin is β-chirality independent. Nucl. Acids Res. 23: 4239–4245.

  42. 42.

    and 1995. Phosphorothioate oligodeoxynucleotides: anti-sense or anti-protein. Antisense Res. Dev. 5: 241.

  43. 43.

    , , and 1995. Targeting peptide nucleic acid protein-conjugates to structural features within duplex DNA. Bioorganic and Medicinal Chemistry 3: 437–445.

Download references

Author information

    • Mieczyslaw A. Piatyszek

    Present address: Geron Corporation, 200 Constitution Dr., Menlo Park, CA 94025.

    • David R. Corey

    e-mail: corey@howie.swmed.edu.

Affiliations

  1. Howard Hughes Medical Institute, Department of Pharmacology

    • James C. Norton
    •  & David R. Corey

  2. Department of Cell Biology and Neuroscience, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, TX 75235.

    • Mieczyslaw A. Piatyszek
    • , Woodring E. Wright
    •  & Jerry W. Shay

Authors

  1. Search for James C. Norton in:

  2. Search for Mieczyslaw A. Piatyszek in:

  3. Search for Woodring E. Wright in:

  4. Search for Jerry W. Shay in:

  5. Search for David R. Corey in:

To obtain permission to re-use content from this article visit RightsLink.

About this article

Publication history

Received

Accepted

Published

DOI

https://doi.org/10.1038/nbt0596-615